|
 |
European BioPharmaceutical Review
|
| Recently, Dr Craig Venter created a stir by announcing that he was, for the princely sum of half a million dollars, providing the opportunity for high net worth individuals (presumably!) to have their whole genome sequenced. In fact, Dr Venter is interested from a scientific standpoint in acquiring comprehensive information about genetic variation in a number of individuals. It is a neat way of funding this endeavour if the individuals are prepared to pay for the activity themselves. But what would they gain for their money? Will useful information be provided or is this just another trophy purchase? Who gets the most out of this unusual contract? The view of some commentators has been that the CD containing their genetic code that these wealthy individuals will receive will have little more than novelty value. They argue that our understanding of the genome is so rudimentary that little interpretative value can be extracted at this stage. |
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
EuroBiopartnering 2008
7-9 October 2008, Paris, France
EuroBiOpartnering
2008 gives you the unique opportunity to meet the relevant decision makers and
opinion leaders from the international biotech community and offers you 3 days
of partnering opportunities including one-to-one meetings, company presentations
and further networking activities…
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Product Development Group, Inc
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >> |
|
 |
